Shots: Sorrento will provide manufacturing support to Celularity as it intends to commence the P-I/II clinical study of CYNK-001 in 89 adults with COVID-19. The addition of Sorrento’s cGMP cell therapy manufacturing capacity is expected to accelerate the rapid scale-up and sustained production of Celularity’s CYNK-001 to be used in its P-I/II study in COVID-19 […]Read More
Shots: The transition to the second phase of development follows the completion of the first phase of securing 300 different types of Abs targeting the antigen last month. The library of Ab was developed utilizing the blood of recovered patients in Korea Celltrion will initiate the screening of Ab to find the most effective one […]Read More
Shots: The update in the development is based on ASPIRO P-I/II study results assessing AT132 in 12 patients aged≤ 5 yrs. following a pre-IND meeting of AT132 with FDA in Dec, 2018 for XLMTM, occurred due to mutations in the MTM1 gene The FDA meeting is in response to review nonclinical, clinical, chemistry, manufacturing and controls […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
